U.S. Auto Stock News

JP Morgan’s downgrade of Cognex (CGNX) to a more cautious rating has put the stock back under the microscope, as investors reassess how its automation story lines up with near term growth expectations. See our latest analysis for Cognex. The downgrade lands after a choppy stretch, with a 30 day share price return of minus 9.62 percent and a 5 year total shareholder return of minus 47.58 percent, signaling that momentum has been fading despite recent operational progress. If this shift in...

GE Vernova (GEV) and Taiwan Power Company just struck a deal for 25 onshore wind repower upgrade kits, plus five years of services, signaling a clear push to scale GE Vernova's renewables footprint in Asia. See our latest analysis for GE Vernova. The deal lands while GE Vernova's share price has climbed to $601.97, with a strong year to date share price return hinting that investors see building momentum behind its renewables and broader energy transition story rather than fading...

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...

GE HealthCare Technologies (GEHC) just used RSNA 2025 to roll out a packed slate of AI imaging launches and new hospital alliances, signaling a deliberate push to own more of the precision medicine workflow. See our latest analysis for GE HealthCare Technologies. The flurry of RSNA product unveilings and new alliances with Mayo Clinic and URMC appears to be resonating, with a roughly 12 percent 1 month share price return and firmer sentiment after tariff driven weakness earlier this year,...

TJX Companies (TJX) just posted another solid quarter, with Q3 2026 revenue of about $15.1 billion, Basic EPS of $1.28, and net income of $1.4 billion setting the tone for its latest update. The company has seen revenue move from roughly $14.1 billion and EPS of $1.15 in Q3 2025 to $15.1 billion and $1.28 this quarter, while trailing twelve month revenue has climbed to about $59.0 billion alongside EPS of $4.58 and net income of $5.1 billion, giving investors a clear view of steady top and...

Cantor Fitzgerald recently reaffirmed its Overweight rating on Intuitive Machines, highlighting the completed Lanteris acquisition and several upcoming NASA-related contract decisions and missions as key near-term catalysts. This cluster of potential Lunar Terrain Vehicle and CLPS CT4 contract awards, alongside the planned IM-3 lunar mission, has sharpened investor focus on how quickly Intuitive Machines can convert technical capabilities into recurring revenue. Next, we’ll explore how the...

Sigma Lithium (SGML) is back in the spotlight after its high profile push at COP30, where management showcased a Quintuple Zero ESG model that directly ties Brazil’s lithium ambitions to cleaner, lower impact production. See our latest analysis for Sigma Lithium. The COP30 spotlight has coincided with a sharp 30 day share price return of 87.02% from Sigma Lithium. Yet its year to date share price return remains negative, and the three year total shareholder return of 71.59% is still deeply...

RLI (RLI) has quietly slipped this year, with the stock down about 23% year to date even as its long term track record and underwriting discipline remain intact. This creates an interesting setup for patient investors. See our latest analysis for RLI. The 6.8% 1 month share price return suggests some buyers are stepping back in after a weak start to the year, even though the year to date share price return is still firmly negative and the 1 year total shareholder return trails its solid 3 and...

AbbVie (ABBV) has packed several catalysts into a few weeks, including fresh blood cancer data heading to ASH 2025, an FDA green light for EPKINLY in follicular lymphoma, and a dividend hike. See our latest analysis for AbbVie. Those oncology and neuroscience wins are landing against a strong tape, with AbbVie’s latest share price at $230.24 and a roughly 28 percent year to date share price return, while its five year total shareholder return of about 157 percent signals durable momentum...

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...

If you are wondering whether Novavax at around $6.84 is a beaten down bargain or a value trap, you are not alone. That is exactly what this breakdown is going to tackle. The stock has slipped recently, with returns of about -1.6% over the last week, -13.5% over the last month and -20.2% year to date, on top of a rough -94.1% over five years. Those moves reflect shifting sentiment around Novavax's vaccine pipeline and its ability to carve out a sustainable niche in a post pandemic market...

In recent days, S&P Global completed a US$1.00 billion private placement of senior unsecured notes due 2031 and 2035, while also announcing new AI data integrations with Amazon Web Services’ Amazon Quick Suite for financial, market, and energy insights. Together, the AI-focused AWS integrations and fresh debt issuance highlight how S&P Global is pairing data innovation with additional financial flexibility for future initiatives. Next, we’ll examine how this combination of new AWS AI...

Wondering if Amneal Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already priced in? Here is a breakdown of what the recent market action is really telling us about its value. The stock has cooled slightly in the last week, down 2.6%, but that comes after a strong 8.9% gain over 30 days, a hefty 57.1% year to date, and an impressive 425.4% over three years. Those moves follow a steady stream of developments around Amneal strengthening its position in...

Wondering if CBIZ is now a bargain or a value trap after its recent slide? This article will walk through the numbers so you can decide with confidence. The stock has bounced 4.9% over the last week, but that is against a much steeper backdrop of a 6.7% drop over 30 days and a painful 36.6% fall year to date, leaving 1 year returns at around -38.4% despite a strong 102.5% gain over 5 years. Those moves have come as investors reassess service focused businesses like CBIZ in a higher rate,...

Comfort Systems USA (FIX) just delivered third quarter results that topped both earnings and revenue forecasts, and management is doubling down with five 2025 acquisitions aimed at strengthening its Electrical segment and multiyear project pipeline. See our latest analysis for Comfort Systems USA. That strong quarter and acquisition spree come on top of a powerful run. The share price is at $949.3 after a 31.13% 90 day share price return and an exceptional 5 year total shareholder return of...

If you are wondering whether Teladoc Health is a beaten-down disaster or a quietly emerging value play at today’s price, you are not alone. That is exactly what this breakdown is here to unpack. The stock has bounced 1.1% over the last week but is still down 7.5% over the past month and a steep 20.9% year to date, capping a brutal 96.1% slide over five years that has reset investor expectations. Those moves have come as Teladoc tries to reposition itself from a hyper-growth pandemic favorite...

Chewy (CHWY) is back in the spotlight after a fresh round of analyst reports zeroed in on its profitability, with repeated gross margin misses putting extra pressure on the stock ahead of earnings. See our latest analysis for Chewy. The latest analyst chatter and profitability worries come after a choppy stretch for the stock, with a 30 day share price return of 3.13% but a 90 day share price return of negative 17.52 percent. This has left longer term total shareholder returns still in...

Plug Power recently began its first-ever contract to supply up to 218,000 kilograms (480,000 pounds) of liquid hydrogen, worth up to US$2.8 million, to NASA’s Glenn Research Center and Neil A. Armstrong Test Facility in Ohio, using its own U.S. production network and cryogenic transport fleet. This NASA award marks Plug Power’s entry into the space sector and showcases its ability to meet high-specification, mission-critical hydrogen requirements beyond its core material-handling...

Saba Capital Management’s latest insider buy in ASA Gold and Precious Metals (ASA), adding over 9,000 shares at around 53 dollars each, puts fresh attention on what this big shareholder might be seeing in the period ahead. See our latest analysis for ASA Gold and Precious Metals. That conviction lines up with a powerful run in ASA’s share price, which now sits at 52.76 dollars after a roughly 14 percent 1 month share price return and a standout 1 year total shareholder return of about 160...

Norfolk Southern (NSC) shares have quietly pushed higher over the past month, and that steady climb is starting to draw fresh attention from investors comparing rail stocks to the broader market. See our latest analysis for Norfolk Southern. That recent strength sits on top of a solid run, with the share price now at $294.05 and a robust year to date share price return suggesting momentum is still building rather than fading, backed by a steady multi year total shareholder return profile. If...

Entergy (ETR) just broke ground on two new combined cycle natural gas plants in north Louisiana, projects regulators approved to boost grid reliability, accommodate Meta’s incoming data center, and support the region’s broader economic expansion. See our latest analysis for Entergy. The stock’s 1 day share price return of 1.37 percent, taking Entergy to 94.24 dollars, builds on a solid year to date share price gain of 24.99 percent and a 5 year total shareholder return of 116.97 percent. This...

In its most recent Q3 update, Marqeta reported year-on-year revenue growth of 27.6% and outperformed analyst estimates for both revenue and EBITDA, supported by stronger-than-expected total payment volume. This outperformance underscores how Marqeta’s card-issuing platform can convert higher transaction activity into improving profitability metrics, an important signal for long-term scalability. We’ll now examine how Marqeta’s better-than-expected Q3 revenue and EBITDA performance may...

Pfizer and Astellas previously announced that the FDA approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda as a perioperative treatment for cisplatin-ineligible adults with muscle-invasive bladder cancer, based on Phase 3 EV-303 data showing strong gains in event-free and overall survival versus surgery alone. This decision strengthens Pfizer’s oncology franchise by moving an advanced antibody-drug conjugate and immunotherapy combination into an earlier, curative-intent setting for...

Arbor Realty Trust recently drew attention after Director William Green bought 12,800 shares on November 28, 2025, adding to a year-long pattern of insider purchases with no reported insider sales. At the same time, analysts have lowered earnings estimates for the current and next fiscal years, highlighting a tension between insider confidence and market caution around Arbor Realty Trust’s outlook. We’ll now examine how this steady insider buying interest may influence Arbor Realty Trust’s...